Skip to Content

Optimer to Present Data on Lead Antibiotic Candidates at ICAAC

SAN DIEGO--(BUSINESS WIRE)--Sep 13, 2007 - Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR), today announced that results of a microbiologic study on the in vitro activity of OPT-80 and its primary metabolite, OP-1118, have been accepted at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) to be held in Chicago, IL, on September 17-20, 2007. Farah Babakhani, PhD, Biology Group Leader at Optimer, will be presenting the results. Optimer's medical affairs booth will be located in Hall D in the Lakeside Center at McCormick Place. -0-
Thursday, September 20 from 9:00am-10:00am Central Time

Presentation number: E-2076

Narrow Spectrum Activity and Low Fecal Protein Binding of OPT-80 and

Its Major Hydrolysis Metabolite (OP-1118)

In addition, results of two studies of ulifloxacin, the active metabolite of Optimer's experimental prodrug antibiotic, prulifloxacin, will be presented by Thomas R. Fritsche, MD, PhD, Associate Director of JMI Laboratories, a contract research laboratory. -0-

Monday, September 17 from 12:00pm-1:00pm Central Time

Presentation number: D-236

Proposed Disk Diffusion (DD) Quality Control (QC) Ranges for

Ulifloxacin (ULI) and Intermethod Comparison Using CLSI Broth

Microdilution and DD.

Wednesday, September 19 from 12:15pm-1:15pm Central Time

Presentation number: E-1638

In Vitro Activity of Ulifloxacin Tested against a Worldwide Collection

of Pathogens Producing Traveler's Diarrhea

About Optimer

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products for the treatment of serious infections. Optimer currently has two late-stage anti-infective product candidates. OPT-80, currently in two pivotal Phase 3 clinical trials, is being developed for the treatment of Clostridium difficile-associated diarrhea, the most common hospital-acquired diarrhea. Prulifloxacin, also currently in two pivotal Phase 3 clinical trials, is an antibiotic being developed for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information regarding Optimer and its products can be found at

Forward-looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to OPT-80, Prulifloxacin, and CDAD. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the timing, progress and likelihood of success of our product research and development programs, the timing and status of our preclinical and clinical development of potential drugs and other risks detailed in Optimer's filings with the Securities and Exchange Commission.


Optimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance

Posted: September 2007